[1] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75: 843-854.
[2] Varol N, Konac E, Gurocak OS. The realm of microRNAs in cancers. Mol Biol Rep, 2011, 38: 1079-1089.
[3] Manikandan J, Aare JJ, Kumar SD, et al. Oncomirs: the potential role of noncoding microRNAs in understanding cancer. Bioinformation, 2008, 2: 330-334.
[4] Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell, 2011, 19: 232-243.
[5] Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006, 3: 87-98.
[6] Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science, 2005, 309: 1577-1581.
[7] Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a,a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 2007, 67: 6092-6099.
[8] Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/b-catenin pathway. Liver Int, 2012, 32: 752-760.
[9] Nassirpour R, Mehta PP, Yin MJ. MiR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One, 2013, 8: e79655.
[10] Fornaril F, Milazzo M, Calin GA, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 2010, 70: 5184-5193.
[11] Song J, Gao L, Yang G, et al. MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One, 2014, 9: e110074.
[12] Shatseva T,Lee DY,Deng Z,et al. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci, 2011, 124: 282-2836.
[13] Shen Q,Cicinnati VR,Zhang X,et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion.Mol Cancer, 2010, 9: 1-12.
[14] Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol, 2011, 45: 355-360.
[15] Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma,promotes apoptosis and suppresses tumorigenicity. Cancer Res, 2009, 69: 1135-1142.
[16] Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of humanhepatocellular carcinoma. FEBS Lett, 2012, 586: 4362-4370.
[17] Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol, 2014, 60: 590-598.
[18] Wang Y, Lu Y, Toh ST, et al. Lethal-7 is down-regulated by thehepatitis B virus X protein and targets signal transducer and activator of transcription 3. J Hepatol, 2010, 53: 57-66.
[19] Cheng JC, Yeh YJ, Tseng CP, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci, 2012, 69: 2621-2633.
[20] Davoodian N, Lotfi AS, Soleimani M, et al. Let-7f microRNA negatively regulates hepatic differentiation of human adipose tissuederived stem cells. J Physiol Biochem, 2014, 70: 781-789.
[21] Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem, 2011, 286: 36677-36685.
[22] Zhang J, Jin H, Liu H, et al. miRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis, 2014, 3: e97.
[23] Gramantieri L, Fornari F, Ferracin M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.Clin Cancer Res, 2009, 15: 5073-5081.
[24] Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C /p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27: 5651-5661.
[25] Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA, 2010, 107: 264-269.
[26] Ding CL, Xu G, Ren H, et al. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner. Virus Res, 2015, 196: 135-139.
[27] Scisciani C,Vossio S,Guerrieri F,et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol, 2012, 56: 855-861.
[28] Li Q, Ding C, Chen C, et al. miR-224 promotion of cell migration and invasion by targeting HomeoboxD10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol, 2014, 29: 835-842.
[29] Wang Y, Toh HC, Chow P, et al. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J, 2012, 26: 3032-3041.
[30] Scisciani C, Vossio S, Guerrieri F, et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol, 2012, 56: 855-861.
[31] Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133: 647-658.
[32] Connolly EC, Van Doorslaer K, Rogler LE, et al. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res, 2010, 8: 691-700.
[33] Xu G, Zhang Y, Wei J, et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer, 2013, 13: 469-477.
[34] Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep, 2012, 27: 1660-1668.
[35] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 2011, 29: 4781-4788.
[36] Ge W, Yu DC, Li QG, et al. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and theirclinical significances. Clin Lab, 2014, 60: 427-434.
[37] Oksuz Z, Serin MS, Kaplan E, et al. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. MolBiol Rep, 2015, 42: 713-720.
[38] Hsu SH, Yu B, Wang X, et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine, 2013, 9: 1169-1180.
[39] Velagapudi SP, Gallo SM, Disney MD. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol, 2014, 10: 291-297. |
